Möchten Sie immer auf dem neuesten Stand bleiben?

ACTG Launches Landmark Study Evaluating Treatments for Depressive Disorders with or without Mild Neurocognitive Disorder among People Living with HIV

The HoT study: an essential new study with the potential to significantly expand the body of knowledge around menopause among women living with HIV

ACTG today announced the publication of “Tecovirimat for the Treatment of Mpox (STOMP)" in NEJM.

ACTG today announced the publication of “Cabotegravir plus Rilpivirine for Persons Living with HIV" in the NEJM.

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IPACE-HIV study.

Treating people living with HIV and metabolic dysfunction-associated MASLD with semaglutide significantly improved biomarkers of cardiovascular risk.

ACTG Presents Findings from REPRIEVE at CROI 2025 Presentations Address Frailty, Inflammation, Asymptomatic Heart Muscle Damage, and Mental Function

ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV

ACTG Presents Data from Mpox Study STOMP at CROI

Presentations highlight relationship between semaglutide and blood markers of gene modification age predictors, gut bacteria, heart and metabolic effects